Viekira XR is a co-formulation of four active ingredients — dasabuvir, ombitasvir, paritaprevir and ritonavir — that are present in Abbvie’s Viekira Pak, which is already on the market.
Viekira XR, taken once daily as three oral tablets, represents the first treatment available for adults with chronic genotype 1 hepatitis C virus that combines three direct-acting antivirals.
North Chicago, Ill.-based AbbVie did not specify when Viekira XR will hit the market.
More articles about the drug market:
‘Pain refugees’ travel out of Montana for access to opioid prescriptions
Sen. Bernie Sanders’ DNC speech tackles high prescription drug costs: 4 things to know
Eli Lily exceeds 2Q expectations thanks to new drug sales
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.